Novel strategies in glioblastoma surgery aim at safe, super-maximum resection in conjunction with local therapies

Chinese Journal of Cancer

Volumn 33, Issue 1, 2014, Pages 8-15

  Wolbers, John G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Extensive surgery; Gene therapy; Glioma; Local chemotherapy; Photodynamic therapy

Indexed keywords

NANOPARTICLE; PHOTOSENSITIZING AGENT;

BOLD SIGNAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CRANIOTOMY; DIFFUSION TENSOR IMAGING; FLUORESCENCE IMAGING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLIOBLASTOMA; HUMAN; NEURONAVIGATION; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR LOCALIZATION;

BRAIN MAPPING; BRAIN NEOPLASMS; CONSCIOUS SEDATION; DIFFUSION TENSOR IMAGING; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MICROSURGERY; MONITORING, INTRAOPERATIVE; NEURONAVIGATION; NEUROSURGICAL PROCEDURES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84891666036     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.013.10219     Document Type: Review

References (46)

1. Deorah S, Lynch CF, Sibenaller ZA, et al. Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001. Neurosurg Focus, 2006,20: E1.
2. Yabroff KR, Harlan L, Zeruto C, et al. Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006. Neuro-Oncol, 2012,14: 351-359.
3. Riemenschneider MJ, Hegi ME, Reifenberger G. MGMT promoter methylation in malignant gliomas. Targeted Oncol, 2010,5:161-165.
4. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg, 2001,95: 190-198.
5. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol, 2009,10: 459-466.
6. Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery, 2008,62: 564-576.
7. Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg, 2011,115: 3-8.
8. McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma: clinical article. J Neurosurg, 2009,110: 156-162.
9. Vecht CJ, Avezaat CJJ, Van Putten WLJ, et al. The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients. J Neurol Neurosurg Psychiat, 1990,53: 466-471.
10. Lun M, Lok E, Gautam S, et al. The natural history of extracranial metastasis from glioblastoma multiforme. J Neuro-Oncol, 2011,105: 261-273.
11. Kundu B, Penwarden A, Wood JM, et al. Association of functional magnetic resonance imaging indices with postoperative language outcomes in patients with primary brain tumors. Neurosurg Focus, 2013,34: E6.
12. Abdullah KG, Lubelski D, Nucifora PG, et al. Use of diffusion tensor imaging in glioma resection. Neurosurg Focus, 2013,34: E1.
13. Nigris DD, Collins DL, Arbel T. Fast rigid registration of pre-operative magnetic resonance images to intra-operative ultrasound for neurosurgery based on high confidence gradient orientations. Int J Comput Assist Radiol Surg, 2013,8: 649-661.
14. Bello L, Castellano A, Fava E, et al. Intraoperative use of diffusion tensor imaging fiber tractography and subcortical mapping for resection of gliomas: technical considerations. Neurosurg Focus, 2010,28: E6.
15. Bulsara KR, Johnson J, Villavicencio AT. Improvements in brain tumor surgery: the modern history of awake craniotomies. Neurosurg Focus, 2005,18: E5.
16. Taylor MD, Bernstein M. Awake craniotomy with brain mapping as the routine surgical approach to treating patients with supratentorial intraaxial tumors: a prospective trial of 200 cases. J Neurosurg, 1999,90: 35-41.
17. Haglund MM, Berger MS, Shamseldin M, et al. Cortical localization of temporal lobe language sites in patients with gliomas. Neurosurgery, 1994,34: 567-576.
18. Sanai N, Berger MS. Intraoperative stimulation techniques for functional pathway preservation and glioma resection. Neurosurg Focus, 2010,28: E1.
19. Szelenyi A, Bello L, Duffau H, et al. Intraoperative electrical stimulation in awake craniotomy: methodological aspects of current practice. Neurosurg Focus, 2010,28: E7.
20. Colditz MJ, Jeffree RL. Aminolevulinic acid (ALA)-protoporphyrin IX fluorescence guided tumour resection. Part 1: Clinical, radiological and pathological studies. J Clin Neurosci, 2012,19: 1471-1474.
21. Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol, 2011,12: 997-1003.
22. Senft C, Forster MT, Bink A, et al. Optimizing the extent of resection in eloquently located gliomas by combining intraoperative MRI guidance with intraoperative neurophysiological monitoring. J Neuro-Oncol, 2012,109: 81-90.
23. Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol, 2006,7: 392-401.
24. Colditz MJ, Leyen KV, Jeffree RL. Aminolevulinic acid (ALA)-protoporphyrin IX fluorescence guided tumour resection. Part 2: Theoretical, biochemical and practical aspects. J Clin Neurosci, 2012,19: 1611-1616.
25. Valdes PA, Fan X, Ji S, et al. Estimation of brain deformation for volumetric image updating in protoporphyrin IX fluorescence-guided resection. Stereotact Funct Neurosurg, 2010,88: 1-10.
26. Wilson BC, Patterson MS. The physics, biophysics and technology of photodynamic therapy. Phys Med Biol, 2008,53: R61-R109.
27. Hage M, Siersema PD, van Dekken H, et al. 5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: a randomised trial. Gut, 2004,53: 785-790.
28. Master A, Livingston M, Sen Gupta A. Photodynamic nanomedicine in the treatment of solid tumors: perspectives and challenges. J Control Release, 2013,168: 88-102.
29. van Zaane F, Subbaiyan D, van den Heuvel A, et al. A telemetric light delivery system for metronomic photodynamic therapy (mPDT) in rats. J Biophotonics, 2010,3: 347-355.
30. Brem H, Ewend MG, Piantadosi S, et al. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. J Neurooncol, 1995, 26: 111-123.
31. Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery, 1997,41: 44-49.
32. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol, 2003,5: 79-88.
33. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 2005,352: 987-996.
34. Grossman SA, Reinhard C, Colvin OM, et al. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg, 1992,76: 640-647.
35. McGirt MJ, Than KD, Weingart JD, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme: clinical article. J Neurosurg, 2009,110: 583-588.
36. Gutenberg A, Lumenta CB, Braunsdorf WEK, et al. The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience. J Neuro-Oncol, 2013,113: 163-174.
37. Juratli TA, Schackert G, Krex D. Current status of local therapy in malignant gliomas-a clinical review of three selected approaches. Pharmacol Ther, 2013.
38. Allhenn D, Boushehri MA, Lamprecht A. Drug delivery strategies for the treatment of malignant gliomas. Int J Pharm, 2012,436: 299-310.
39. Sampson JH, Archer G, Pedain C, et al. Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg, 2010,113: 301-309.
40. Wirth T, Parker N, Yla-Herttuala S. History of gene therapy. Gene, 2013,525: 162-169.
41. Cheng R, Meng F, Deng C, et al. Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. Biomaterials, 2013,34: 3647-3657.
42. Tobias A, Ahmed A, Moon KS, et al. The art of gene therapy for glioma: a review of the challenging road to the bedside. J Neurol Neurosurg Psychiatry, 2013,84: 213-222.
43. Aboody K, Capela A, Niazi N, et al. Translating stem cell studies to the clinic for CNS repair: current state of the art and the need for a Rosetta stone. Neuron, 2011,70: 597-613.
44. Aboody KS, Najbauer J, Metz MZ, et al. Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies. Sci Transl Med, 2013,5: 184ra159.
45. Bexell D, Svensson A, Bengzon J. Stem cell-based therapy for malignant glioma. Cancer Treat Rev, 2013,39: 358-365.
46. Cai C, Yuan Y, Johnson VE. Bayesian adaptive phase II screening design for combination trials. Clin Trials, 2013,10: 353-362.